AbbVie and Iambic have entered a multi-year collaboration to accelerate the discovery and development of small-molecule therapies using artificial intelligence. The partnership will focus on potential first- and best-in-class medicines across immunology, neuroscience and oncology, combining AbbVie's drug discovery expertise with Iambic's AI-powered molecular design platform.
The collaboration is designed to improve how researchers identify and optimize promising drug candidates. Traditional small-molecule discovery requires scientists to evaluate numerous properties individually, which can make candidate optimization complex and time-consuming. Iambic's platform instead uses AI to analyze and optimize multiple molecular characteristics simultaneously, helping researchers test more potential designs and prioritize candidates with stronger development profiles.
Central to the partnership is Iambic's molecular superintelligence platform, powered by technologies including Enchant and NeuralPLexer. The companies will use Enchant v3, a multimodal transformer model trained across more than 6,000 molecular properties and multiple types of biomedical data. The technology allows researchers to evaluate numerous drug design hypotheses in parallel while predicting properties relevant to both discovery and development.
AbbVie plans to integrate these capabilities with its internal discovery teams to improve molecular design decisions, shorten research timelines and potentially increase the probability that promising candidates successfully advance through development. The partnership reflects the pharmaceutical industry's broader adoption of AI as a tool for navigating complex biological and chemical datasets during early-stage drug discovery.
Under the agreement, Iambic will receive an upfront payment and will be eligible for additional milestone payments based on the collaboration's success, as well as tiered royalties on net sales of resulting products. Financial details of the upfront payment and potential milestones were not disclosed.
Click here to read the original news story.
